Zefan Li1, Jing Zhang1, Hui-Wang Ai1. 1. Department of Molecular Physiology and Biological Physics, and Center for Membrane and Cell Physiology, University of Virginia, Charlottesville, Virginia 22908, United States.
Abstract
Uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) is a nucleotide sugar used by glycosyltransferases to synthesize glycoproteins, glycosaminoglycans, glycolipids, and glycoRNA. UDP-GlcNAc also serves as the donor substrate for forming O-GlcNAc, a dynamic intracellular protein modification involved in diverse signaling and disease processes. UDP-GlcNAc is thus a central metabolite connecting nutrition, metabolism, signaling, and disease. There is a great interest in monitoring UDP-GlcNAc in biological systems. Here, we present the first genetically encoded, green fluorescent UDP-GlcNAc sensor (UGAcS), an optimized insertion of a circularly permuted green fluorescent protein (cpGFP) into an inactive mutant of an Escherichia coli UDP-GlcNAc transferase, for ratiometric monitoring of UDP-GlcNAc dynamics in live mammalian cells. Although UGAcS responds to UDP-GlcNAc quite selectively among various nucleotide sugars, UDP and uridine triphosphate (UTP) interfere with the response. We thus developed another biosensor named UXPS, which is responsive to UDP and UTP but not UDP-GlcNAc. We demonstrated the use of the biosensors to follow UDP-GlcNAc levels in cultured mammalian cells perturbed with nutritional changes, pharmacological inhibition, and knockdown or overexpression of key enzymes in the UDP-GlcNAc synthesis pathway. We further utilized the biosensors to monitor UDP-GlcNAc concentrations in pancreatic MIN6 β-cells under various culture conditions.
Uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) is a nucleotide sugar used by glycosyltransferases to synthesize glycoproteins, glycosaminoglycans, glycolipids, and glycoRNA. UDP-GlcNAc also serves as the donor substrate for forming O-GlcNAc, a dynamic intracellular protein modification involved in diverse signaling and disease processes. UDP-GlcNAc is thus a central metabolite connecting nutrition, metabolism, signaling, and disease. There is a great interest in monitoring UDP-GlcNAc in biological systems. Here, we present the first genetically encoded, green fluorescent UDP-GlcNAc sensor (UGAcS), an optimized insertion of a circularly permuted green fluorescent protein (cpGFP) into an inactive mutant of an Escherichia coli UDP-GlcNAc transferase, for ratiometric monitoring of UDP-GlcNAc dynamics in live mammalian cells. Although UGAcS responds to UDP-GlcNAc quite selectively among various nucleotide sugars, UDP and uridine triphosphate (UTP) interfere with the response. We thus developed another biosensor named UXPS, which is responsive to UDP and UTP but not UDP-GlcNAc. We demonstrated the use of the biosensors to follow UDP-GlcNAc levels in cultured mammalian cells perturbed with nutritional changes, pharmacological inhibition, and knockdown or overexpression of key enzymes in the UDP-GlcNAc synthesis pathway. We further utilized the biosensors to monitor UDP-GlcNAc concentrations in pancreatic MIN6 β-cells under various culture conditions.
Uridine
diphosphate N-acetylglucosamine (UDP-GlcNAc),
the major end-product of the hexosamine biosynthetic pathway (HBP),
is one of the most important nucleotide sugars in living organisms.[1] The HBP branches out from glycolysis and consumes
∼0.006–3% of total glucose,[2−4] along with glutamine,
acetyl-coenzyme A (Ac-CoA), adenosine triphosphate (ATP), and uridine
triphosphate (UTP). Because multiple types of metabolic molecules,
including carbohydrates, amino acids, fatty acids, and nucleotides,
regulate the flux of HBP, UDP-GlcNAc has been considered an integrator
of nutritional and metabolic signals.[5,6]As an
activated N-acetylglucosamine (GlcNAc) donor,
UDP-GlcNAc is vital for the glycosyltransferase-catalyzed formation
of various glycosaminoglycans, glycoproteins, glycolipids, and glycoRNAs.[1,7] In mammalian cells, glycosylation primarily occurs in the endoplasmic
reticulum (ER) and Golgi. The glycosylated products are typically
translocated to the extracellular space, playing critical roles such
as maintaining structural stability, modulating cell–matrix
or cell–cell interaction, regulating cell proliferation and
migration, and initiating other types of signaling.[1,6] Moreover,
UDP-GlcNAc is an essential substrate for O-GlcNAcylation,
a reversible post-translational modification of nucleocytoplasmic
proteins.[2,8,9]O-GlcNAc transferase (OGT) catalyzes the transfer of the GlcNAc subunit
from UDP-GlcNAc to the serine or threonine residues of proteins, while O-GlcNAcase (OGA) hydrolyzes the modification to generate
free proteins and GlcNAc. This dynamic and tightly regulated process,
analogous to more well-known phosphorylation, is involved in a large
array of intracellular signaling processes.[1,5,6,10−12] Aberrant O-GlcNAcylation has been linked to aging,
neurodegeneration, cancer, cardiovascular diseases, and metabolic
disorders.[2,6,13−15]The concentration of UDP-GlcNAc is one of the several key
factors
regulating glycosylation. The drastic increase of the β1,6-branched
oligosaccharide levels was observed in B16 melanoma cells incubated
with GlcNAc.[16] In another example, deleterious
mutations in SLC35A3, the major Golgi UDP-GlcNAc transporter, were
identified in patients with autism spectrum disorder, arthrogryposis,
and epilepsy.[17] These mutations reduce
UDP-GlcNAc transport into the ER, leading to a massive decrease of
highly branched N-glycans and a drastic increase
of lower branched glycoforms at the cell surface.[17] The UDP-GlcNAc level has also been found to regulate intracellular O-GlcNAcylation. In vitro characterization
of OGT demonstrated that the concentration of UDP-GlcNAc was positively
correlated with the O-GlcNAcylation of the tested
peptide substrates.[18] Supplementing human
hepatocellular carcinoma HepG2 cells with glucosamine, a metabolite
used by HBP to synthesize UDP-GlcNAc, significantly increased O-GlcNAc.[19,20] Furthermore, hyperglycemia was
shown to increase the O-GlcNAc level in multiple
tissue types via the HBP.[21−23]Because of the importance
of UDP-GlcNAc in metabolic sensing, signaling,
and disease, methods for monitoring UDP-GlcNAc levels in living systems
are highly needed. Traditionally, chromatography methods are used
to determine cellular UDP-GlcNAc levels,[3,24,25] but these methods require cell lysis and provide
little spatiotemporal resolution. To address this technical gap, we
engineered the first genetically encoded fluorescent sensor, UGAcS,
for detecting UDP-GlcNAc in living cells. We inserted a cpGFP into
an inactive mutant of murG,[26−28] an Escherichia
coli UDP-GlcNAc transferase, and performed directed
evolution to optimize the biosensor. Because UDP and UTP interfere
with the response of UGAcS to UDP-GlcNAc, we developed an additional
control biosensor, UXPS, which is only responsive to UDP and UTP.
We demonstrated the use of the biosensors to follow UDP-GlcNAc concentration
changes in cultured mammalian cells in response to various nutritional,
pharmacological, and genetic perturbations.
Results and Discussion
Design,
Engineering, and in Vitro Characterization
of the UGAcS
MurG is a well-characterized E. coli UDP-GlcNAc transferase involved in synthesizing
lipid-linked precursors to assemble peptidoglycan, the polymeric cell
wall outside the bacterial cell membrane.[28,29] MurG has a high binding affinity to UDP-GlcNAc (∼1.4 μM),
and its structures in the apo and UDP-GlcNAc-bound forms have been
reported.[27,29] We selected murG as the sensory domain to
build a UDP-GlcNAc sensor. By carefully examining the structures of
murG, we identified that the binding of UDP-GlcNAc triggers a structural
conversion of residues 60–70 in murG from a loop into an α-helix
(Supporting Information, Figure S1). We
further confirmed the significant conformation change at this loop
by analyzing the changes of dihedral angles of every four consecutive
Cα atoms (Figure S2).We next inserted cpGFP to the above-identified loop between residues
64 and 65 of murG (Figure A and Figure S3). A fully randomized
residue was introduced to each of the two junctions as the linkers.
We screened the library and identified a UGAcS0.1 mutant with a 30%
response ((R – R0)/R0 or ΔR/R0, where R is the ratio of
fluorescence with 488 nm excitation to that with 400 nm excitation)
to UDP-GlcNAc. To increase the sensor’s response to UDP-GlcNAc,
we performed three rounds of error-prone PCR, and the screening of
these libraries resulted in UGAcS0.2 showing a 300% (ΔR/R0) response.
Figure 1
Design and in
vitro characterization of the biosensors.
(A) Illustration of the sensor design, showing the cpGFP insertion
between residues 64 and 65 of the murG glycosyltransferase. Also highlighted
is a UDP-GlcNAc molecule in the substrate-binding pocket. (B) Fluorescence
excitation and emission spectra of UGAcS before and after addition
of 1 mM UDP-GlcNAc. Responses of UGAcS (C) or UXPS (D), presented
as normalized fluorescence excitation ratios (488 nm/400 nm), to 100
μM of various nucleoside sugars and other related cellular metabolites.
Data are presented as mean ± SD (n = 3 technical
repeats). Dose-dependent responses of UGAcS (E) or UXPS (F) to UDP
or UDP-GlcNAc.
Design and in
vitro characterization of the biosensors.
(A) Illustration of the sensor design, showing the cpGFP insertion
between residues 64 and 65 of the murG glycosyltransferase. Also highlighted
is a UDP-GlcNAc molecule in the substrate-binding pocket. (B) Fluorescence
excitation and emission spectra of UGAcS before and after addition
of 1 mM UDP-GlcNAc. Responses of UGAcS (C) or UXPS (D), presented
as normalized fluorescence excitation ratios (488 nm/400 nm), to 100
μM of various nucleoside sugars and other related cellular metabolites.
Data are presented as mean ± SD (n = 3 technical
repeats). Dose-dependent responses of UGAcS (E) or UXPS (F) to UDP
or UDP-GlcNAc.Although our primary goal is to
apply the fluorescent biosensors
in mammalian cells, and murG is unlikely to be active in mammalian
cells where its lipid-linked peptidoglycan substrate is not present,
we still performed saturation mutagenesis on the catalytic His19 residue
of murG in UGAcS0.2. This residue is essential for catalysis and conserved
in murG from 73 orthologues.[26,27] Our screening of the
mutants led to an enzymatically inactive His19Ser mutant (UGAcS0.3)
but is comparable to UGAcS0.2 in terms of the UDP-GlcNAc responsiveness.Because UDP is a natural inhibitor and regulator of UDP-sugar transferases,
we examined the fluorescence of UGAcS0.3 upon the addition of UDP.
UGAcS0.3 showed a higher response to UDP than UDP-GlcNAc. Therefore,
we next devoted our effort to engineering UGAcS0.3 for increased specificity
to UDP-GlcNAc versus UDP. We chose five pairs of residues (residues
192 and 193, residues 16 and 127, residues 164 and 269, or residues
244 and 245) in the ligand-binding pocket and performed saturation
mutagenesis. Screening of these libraries resulted in UGAcS0.4 with
mutations at residues 192 and 193. In comparison with UGAcS0.3, UGAcS0.4
showed increased responsiveness to UDP-GlcNAc and reduced responsiveness
to UDP. Despite the progress, we were unable to identify a mutant
to exclude the UDP interference entirely.From UGAcS0.4, we
performed two more rounds of random mutagenesis.
By screening these libraries for improved UDP-GlcNAc responsiveness,
we arrived at UGAcS, which showed a nearly 700% response (ΔR/R0) to 1 mM UDP-GlcNAc (Figure B and Figure S4). We further tested the specificity
of UGAcS using various nucleotide sugars and other related compounds
at physiologically relevant concentrations (Figure C). UGAcS responded to UDP-GlcNAc, UDP, and
UTP. Other tested nucleotide sugars, including uridine diphosphate N-acetylgalactosamine (UDP-GalNAc) and uridine diphosphate
glucose (UDP-Glc) that are structurally very close to UDP-GlcNAc,
induced little fluorescence change.After we realized that it
might be unrealistic to engineer a fully
specific UDP-GlcNAc biosensor from the glycosyltransferase, we sought
to identify a UDP sensor, which could be used as a control to cross-check
the responses of the UGAcS variants. From one of the ligand-binding-pocket
mutagenesis libraries mentioned above, we identified a mutant (UXPS),
which is responsive to UDP and UTP, not to UDP-GlcNAc and other nucleotide
sugars (Figure D and Figure S4).We next titrated UGAcS and
UXPS with various concentrations of
UDP-GlcNAc and UDP (Figure E,F). The apparent dissociation constant (Kd) values (deduced from the fluorescence responses of
the sensors) for UGAcS were determined to be 72 ± 4 and 26 ±
1 μM in the presence of UDP-GlcNAc and UDP, respectively, while
UXPS responded to UDP with an apparent Kd of 6 ± 1 μM.
Monitoring of UDP-GlcNAc Changes in HEK 293T
Cells
2-Deoxy-d-glucose (2-DG) is a glucose analogue,
and 2-deoxy-d-glucose-6-phosphate (2-DG6P) intracellularly
formed from 2-DG
competitively inhibits hexokinase (HK) and phosphoglucose isomerase
(PGI), the enzymes involved in the first two steps of glycolysis (Figure A).[30] To validate the function of UGAcS in mammalian cells, we
expressed the sensors in human embryonic kidney (HEK) 293T cells and
examined sensor responses to glycolysis inhibition by 2-DG. HEK293T
cells transiently expressing UGAcS emitted strong green fluorescence.
Upon 3 h of incubation with 10 mM 2-DG, the ratio of the fluorescence
with 488 nm excitation to that with 400 nm excitation (denoted as R488/400) decreased by ∼27.6% (Figure B). The fluorescence
change could be reversed by washing out 2-DG, confirming the reversibility
of UGAcS. Meanwhile, we expressed the control sensor UXPS in HEK 293T
cells and treated the cells using the same procedure. The fluorescence
change of UXPS was minimal, and the magnitude of the difference was
not statistically significant (Figure C).
Figure 2
UDP-GlcNAc level changes in HEK 293T cells perturbed with
2-DG.
(A) Schematic illustration of the hexosamine biosynthetic pathway
(HBP) responsible for the production of UDP-GlcNAc. 2-DG (2-deoxy-d-glucose) is a glycolysis inhibitor acting on hexokinase (HK)
and phosphoglucose isomerase (PGI), which are highlighted in magenta.
Responses of UGAcS (B) or UXPS (C), given as normalized fluorescence
excitation ratios (488 nm/400 nm), to 3 h of incubation with 10 mM
2-DG, or 3 h of 10 mM 2-DG incubation followed by washout and an addition
3 h culture in normal medium. (D) HILIC-MS analysis of relative UDP-HexNAc
concentrations in extracts of HEK 293T cells untreated or treated
with 10 mM 2-DG. (E) Representative mass spectrograms of the samples
in panel D. The m/z = 606 peak represents
the major isotope peak for UDP-HexNAc. 13C-double-labeled
UDP-GlcNAc (13C2-UDP-GlcNAc) was doped into
the cell extracts as an internal standard, contributing primarily
to the m/z = 608 peak. Data in panels
B–D are presented as mean ± SEM (n =
3 wells of cells for each group). P values were determined
by one-way ANOVA with Dunnett’s multiple comparisons test (***P < 0.001; *P < 0.05; and n.s., not
significant, P ≥ 0.05).
UDP-GlcNAc level changes in HEK 293T cells perturbed with
2-DG.
(A) Schematic illustration of the hexosamine biosynthetic pathway
(HBP) responsible for the production of UDP-GlcNAc. 2-DG (2-deoxy-d-glucose) is a glycolysis inhibitor acting on hexokinase (HK)
and phosphoglucose isomerase (PGI), which are highlighted in magenta.
Responses of UGAcS (B) or UXPS (C), given as normalized fluorescence
excitation ratios (488 nm/400 nm), to 3 h of incubation with 10 mM
2-DG, or 3 h of 10 mM 2-DG incubation followed by washout and an addition
3 h culture in normal medium. (D) HILIC-MS analysis of relative UDP-HexNAc
concentrations in extracts of HEK 293T cells untreated or treated
with 10 mM 2-DG. (E) Representative mass spectrograms of the samples
in panel D. The m/z = 606 peak represents
the major isotope peak for UDP-HexNAc. 13C-double-labeled
UDP-GlcNAc (13C2-UDP-GlcNAc) was doped into
the cell extracts as an internal standard, contributing primarily
to the m/z = 608 peak. Data in panels
B–D are presented as mean ± SEM (n =
3 wells of cells for each group). P values were determined
by one-way ANOVA with Dunnett’s multiple comparisons test (***P < 0.001; *P < 0.05; and n.s., not
significant, P ≥ 0.05).To cross-verify the results, we adapted a hydrophilic interaction
chromatography–mass spectrometry (HILIC-MS) method to quantify
UDP-GlcNAc from cell extracts.[3,31] Briefly, we prepared
the lysates of HEK 293T cells treated or untreated with 2-DG and doped
in 13C-double-labeled UDP-GlcNAc (13C2-UDP-GlcNAc) as an internal standard. The samples were separated
on a zwitterionic polymer-based high-performance liquid chromatography
(HPLC) column before being fused into an electrospray ionization (ESI)
single quadrupole mass spectrometer. 606 and 608 m/z ions, which are the major isotope peaks for UDP-GlcNAc
and 13C2-UDP-GlcNAc, respectively, were monitored
(Figure S5). The intensity ratio of the
two peaks is thus an indicator for the relative UDP-GlcNAc concentrations
in the cell lysates. Since our chromatographic condition did not separate
UDP-GlcNAc from UDP-GalNAc, and the two nucleotide sugars have identical
molecular formulas, the HILIC-MS method in fact measured UDP-GlcNAc
and UDP-GalNAc (referred to as UDP-HexNAc) collectively. Specific
epimerases are responsible for the interconversion of UDP-GlcNAc and
UDP-GalNAc in cells. The concentration ratio of UDP-GlcNAc to UDP-GalNAc
is usually ∼3:1.[32] Thus, the UDP-HexNAc
measurements from HILIC-MS can be used to approximate UDP-GlcNAc level
changes. The HILIC-MS analysis confirmed that 2-DG reduced the UDP-HexNAc
level by ∼13.4% (Figure D,E), and the result corroborates the UGAcS-based fluorescence
assay.The glutamine fructose-6-phosphate aminotransferase (GFAT)
is a
feedback-regulated rate-limiting enzyme in the HBP.[33] Since glucosamine (GlcN) enters the HBP downstream of GFAT
(Figure A), GlcN is
a potent stimulator of HBP and can rapidly increase the intracellular
concentration of UDP-GlcNAc.[20] We used
a confocal microscope equipped with 488 and 405 nm lasers to follow
GlcN-stimulated UDP-GlcNAc elevation in HEK 293T cells. Upon GlcN
stimulation, the fluorescence with 488 nm excitation increased along
with the simultaneous decrease of the fluorescence with 405 nm excitation
(Figure A,B), resulting
in an overall ∼70% ratiometric change (ΔR/R0). Most of the change was completed
within the first 30 min poststimulation. In contrast, GlcN triggered
an ∼33% ratiometric change (ΔR/R0) of the UXPS fluorescence in the opposite
direction (Figure C,D). The observed fluorescence change of UXPS is not surprising
because the GlcN-dependent UDP-GlcNAc synthesis process may consume
UTP quickly. Although the opposite responses of UGAcS and UXPS can
exclude the possibility of the observed UGAcS response being caused
by pH changes, we further introduced Arg164Ala and Glu269Ala double
mutations into UXPS, resulting in a deactivated mutant (termed dUGAcS)
unresponsive to UDP-GlcNAc, UTP, and UDP (Figure S6). We tested dUGAcS-expressing HEK 293T cells against GlcN
stimulation and observed no response (Figure E,F). Collectively, these results confirmed
that GlcN indeed increased the intracellular UDP-GlcNAc concentration
and that UGAcS successfully detected this relatively rapid increase
of UDP-GlcNAc in HEK 293T cells.
Figure 3
Glucosamine (GlcN)-induced UDP-GlcNAc
increase in HEK 293T cells.
Representative ratiometric images of HEK 293T cell expressing UGAcS
(A), UXPS (C), or dUGAcS (E) with two excitation wavelengths (488
nm/405 nm) before and after treatment with 5 mM GlcN (scale bars,
40 μm). Quantitative traces of normalized fluorescence excitation
ratios (488 nm/405 nm) for UGAcS (B), UXPS (D), or dUGAcS (F) in HEK
293T cells. Data are presented as mean ± SD (n = 10 cells from 3 replicating wells for each group).
Glucosamine (GlcN)-induced UDP-GlcNAc
increase in HEK 293T cells.
Representative ratiometric images of HEK 293T cell expressing UGAcS
(A), UXPS (C), or dUGAcS (E) with two excitation wavelengths (488
nm/405 nm) before and after treatment with 5 mM GlcN (scale bars,
40 μm). Quantitative traces of normalized fluorescence excitation
ratios (488 nm/405 nm) for UGAcS (B), UXPS (D), or dUGAcS (F) in HEK
293T cells. Data are presented as mean ± SD (n = 10 cells from 3 replicating wells for each group).We next utilized the biosensors to examine UDP-GlcNAc concentration
changes in response to the genetic disruption of two key enzymes in
the HBP. GFAT is the first and rate-limiting enzyme, while UDP-N-acetylglucosamine pyrophosphorylase (UAP) is the last
enzyme in the pathway and is responsible for the direct synthesis
of UDP-GlcNAc (Figure A). We used short hairpin RNAs (shRNAs) to knock down GFAT or UAP.
The effectiveness of the shRNAs was first confirmed using fluorescence
assays with HEK 293T cells coexpressing corresponding shRNAs and the
GFAT1 or UAP1 gene fused to a red fluorescent protein (RFP) mScarlet-I
via a P2A self-cleaving peptide, as well as reverse transcription-quantitative
PCR (RT-qPCR) assays (Figure S7). The GFAT
and UAP shRNA variants that induced the most significant decrease
of mScarlet-I fluorescence and mRNA abundance were selected for further
experiments. A scramble nontargeting shRNA sequence (shNC) was included
as a negative control. Next, we used the shRNA lentiviral vectors
to infect HEK 293T cells, to which the gene of UGAcS or UXPS was further
introduced by transfection. As expected, GFAT or UAP knockdown decreased
the UDP-GlcNAc level, as the fluorescence excitation ratios (R488/400) of UGAcS were reduced compared to the
shNC control group (Figure B). Meanwhile, the fluorescence excitation ratios (R488/400) of UXPS in the experimental groups
were slightly higher (statistically insignificant) than the shNC control
group (Figure C).
Furthermore, the same response trend was observed when GFAT was pharmacologically
inhibited using DON (6-diazo-5-oxo-l-norleucine) (Figure S8).
Figure 4
UDP-GlcNAc level changes in response to
knockdown or overexpression
of GFAT or UAP in HEK 293T cells. (A) Schematic illustration of the
HBP UDP-GlcNAc synthesis pathway. Highlighted in magenta are the two
enzymes selected for genetic manipulation in this study. Responses
of UGAcS (B) or UXPS (C), presented as normalized fluorescence excitation
ratios (488 nm/400 nm), to shRNA knockdown of GFAT or UAP. A negative
shRNA control, shNC, was used for comparison and normalization. Responses
of UGAcS (D) or UXPS (E), given as normalized fluorescence excitation
ratios (488 nm/400 nm), to the overexpression of UAP1-P2A-mScarlet-I
or GFAT1-P2A-mScarlet-I. The overexpression of mScarlet-I alone was
used for comparison and normalization. Data in panels B–E are
presented as mean ± SEM (n = 3 wells of cells
for each group). P values were determined by one-way
ANOVA with Dunnett’s multiple comparisons test (****P < 0.0001; **P < 0.01; *P < 0.05; and n.s., not significant, P ≥ 0.05).
UDP-GlcNAc level changes in response to
knockdown or overexpression
of GFAT or UAP in HEK 293T cells. (A) Schematic illustration of the
HBP UDP-GlcNAc synthesis pathway. Highlighted in magenta are the two
enzymes selected for genetic manipulation in this study. Responses
of UGAcS (B) or UXPS (C), presented as normalized fluorescence excitation
ratios (488 nm/400 nm), to shRNA knockdown of GFAT or UAP. A negative
shRNA control, shNC, was used for comparison and normalization. Responses
of UGAcS (D) or UXPS (E), given as normalized fluorescence excitation
ratios (488 nm/400 nm), to the overexpression of UAP1-P2A-mScarlet-I
or GFAT1-P2A-mScarlet-I. The overexpression of mScarlet-I alone was
used for comparison and normalization. Data in panels B–E are
presented as mean ± SEM (n = 3 wells of cells
for each group). P values were determined by one-way
ANOVA with Dunnett’s multiple comparisons test (****P < 0.0001; **P < 0.01; *P < 0.05; and n.s., not significant, P ≥ 0.05).We also examined the
impact of overexpressing GFAT1 or UAP1 on
the UDP-GlcNAc level. The sensor responses are opposite to those in
the knockdown experiments: GFAT1 or UAP1 overexpression increased
the fluorescence excitation ratios (R488/400) of UGAcS and decreased the fluorescence excitation ratios (R488/400) of UXPS (Figure D,E). Moreover, in both the knockdown and
overexpression experiments, manipulating the GFAT1 expression level
induced more dramatic fluorescence responses than manipulating UAP1.
This is again expected because GFAT plays the rate-limiting role in
the HBP.
Imaging of UDP-GlcNAc Levels in Pancreatic MIN6 β-Cells
Pancreatic β-cells are responsible for the synthesis and
secretion of insulin, a key endocrine regulator of glucose levels
in the blood and other tissues.[34] The glucose
metabolism of pancreatic β-cells is tightly coupled to insulin
synthesis and secretion.[34] Meanwhile, O-GlcNAc levels in β-cells have been linked to the
regulation of insulin gene expression, proinsulin-to-insulin processing,
and glucose-stimulated insulin secretion.[35−37] In this context,
we used our new biosensors to examine UDP-GlcNAc levels in MIN6 β-cells,
a mouse insulinoma cell line, in response to various nutritional conditions.
Expression of the biosensors in MIN6 cells resulted in bright green
fluorescence. Upon 5 mM GlcN stimulation, the fluorescence excitation
ratios (R488/400) of UGAcS-expressing
cells increased by ∼30% (Figure AB) within 1 h. In contrast, an ∼25% decrease
was observed for UXPS-expressing cells (Figure CD), and no response was observed for dUGAcS-expressing
cells (Figure S9A,B). The results suggest
that GlcN, which bypasses the rate-limiting GFAT in the HBP, can stimulate
the biosynthesis of UDP-GlcNAc in MIN6 cells in a manner similar to
that in HEK 293T cells.
Figure 5
Imaging of UDP-GlcNAc levels in pancreatic MIN6
β-cells.
Representative ratiometric images of a MIN6 cell expressing UGAcS
(A) or UXPS (C) with two excitation wavelengths (488 nm/405 nm) before
and after a 1 h treatment with 5 mM GlcN (scale bars, 40 μm).
Responses of UGAcS (B) or UXPS (D), given as normalized fluorescence
excitation ratios (488 nm/405 nm), to 1 h of incubation with 5 mM
GlcN. Representative ratiometric images of MIN6 cells expressing UGAcS
(E) or UXPS (G) with two excitation wavelengths (488 nm/405 nm) cultured
in high (25 mM), low (2 mM), or no glucose DMEM (scale bars, 40 μm).
Responses of UGAcS (F) or UXPS (H), given as normalized fluorescence
excitation ratios (488 nm/405 nm), after replacing high glucose (25
mM) medium with low (2 mM) or no glucose medium for 20 h. Data in
panels B, D, F, and H are presented as mean ± SEM (n = 12 cells from 3 replicating wells for each group). P values in panels B and D were determined by an unpaired two-tailed t-test (**P < 0.01). P values in panels F and H were determined by one-way ANOVA with Tukey’s
multiple comparisons test (***P < 0.001; **P < 0.01; and n.s., not significant, P ≥ 0.05).
Imaging of UDP-GlcNAc levels in pancreatic MIN6
β-cells.
Representative ratiometric images of a MIN6 cell expressing UGAcS
(A) or UXPS (C) with two excitation wavelengths (488 nm/405 nm) before
and after a 1 h treatment with 5 mM GlcN (scale bars, 40 μm).
Responses of UGAcS (B) or UXPS (D), given as normalized fluorescence
excitation ratios (488 nm/405 nm), to 1 h of incubation with 5 mM
GlcN. Representative ratiometric images of MIN6 cells expressing UGAcS
(E) or UXPS (G) with two excitation wavelengths (488 nm/405 nm) cultured
in high (25 mM), low (2 mM), or no glucose DMEM (scale bars, 40 μm).
Responses of UGAcS (F) or UXPS (H), given as normalized fluorescence
excitation ratios (488 nm/405 nm), after replacing high glucose (25
mM) medium with low (2 mM) or no glucose medium for 20 h. Data in
panels B, D, F, and H are presented as mean ± SEM (n = 12 cells from 3 replicating wells for each group). P values in panels B and D were determined by an unpaired two-tailed t-test (**P < 0.01). P values in panels F and H were determined by one-way ANOVA with Tukey’s
multiple comparisons test (***P < 0.001; **P < 0.01; and n.s., not significant, P ≥ 0.05).Next, MIN6 cells expressing
these biosensors were subjected to
glucose deprivation (replacing 25 mM glucose medium with 2 mM or no
glucose medium) and imaged 20 h later. The fluorescence excitation
ratio (R488/400) of UGAcS under the no
glucose condition was ∼50% lower than that under the 25 mM
glucose condition, while we only observed a quite minimal decrease
(statistically insignificant) of the fluorescence excitation ratio
(R488/400) of UGAcS from the 25 mM to
the 2 mM glucose condition (Figure E,F). The fluorescence changes of UXPS (Figure G,H) or dUGAcS (Figure S9C,D) were not significant under all
conditions. We further examined the time course of UGAcS fluorescence
changes in MIN6 cells from 25 to 0 mM glucose and found that 10 h
of glucose deprivation was adequate to complete all fluorescence changes
(Figure S10). Taken together, the UDP-GlcNAc
level in MIN6 cells was sensitive to severe hypoglycemia but relatively
insensitive to glucose concentration changes from 25 to 2 mM within
the examined time frame. These findings corroborate a recent study
on the mouse heart tissue with 5.5 and 25 mM glucose, which concluded
that glucose availability alone does not regulate the HBP flux.[3] In other studies, UDP-GlcNAc has been shown to
directly inhibit GFAT via a negative feedback mechanism.[33,38] The tight regulation of the HBP, however, does not necessarily undermine
the importance of UDP-GlcNAc in nutritional signaling. First, multiple
types of metabolic molecules are funneled into the HBP, and a collection
of these molecules may be needed to drastically shift the HBP flux.
In addition, the GFAT expression level and activity are highly responsive
to other signals, and the HBP is thus likely regulated to different
extents in diverse tissue types and under various pathophysiological
conditions.[39−41]
Conclusion
We have engineered a
genetically encoded UDP-GlcNAc sensor (UGAcS)
by inserting cpGFP into an inactivated UDP-GlcNAc transferase. Because
UGAcS is also responsive to UDP and UTP, we further engineered a control
sensor, UXPS, which is only responsive to UDP and UTP but not UDP-GlcNAc.
We successfully applied the biosensors to monitoring UDP-GlcNAc level
changes in HEK 293T cells in response to 2-DG-induced glycolysis inhibition,
glucosamine stimulation, DON-induced GFAT inhibition, and the genetic
manipulation of two key enzymes (GFAT and UAP) in the HBP. Finally,
we used our biosensors to monitor UDP-GlcNAc levels in pancreatic
MIN6 β-cells under various cell culture conditions. Our results
suggest that glucose metabolism via the HBP is tightly regulated across
a large glucose concentration range. Further research is clearly needed
to further understand the regulatory mechanism of the HBP flux, and
the fluorescent biosensors described here should facilitate these
studies.In addition to being used as research tools in studying
the crucial
roles of UDP-GlcNAc in disease and normal conditions, the biosensors
may have translational applications. Modulation of the HBP has been
considered as a promising method to treat diseases, such as cancer
and diabetes.[42,43] We envision the use of the biosensors
to screen for chemical or genetic modulators of the HBP. In addition,
murG is a key enzyme for peptidoglycan synthesis in bacteria,[44] so these murG-based biosensors may be used to
discover novel murG inhibitors as a new class of antibiotics.Our effort to develop the first genetically encoded nucleotide
sugar sensor will spur the development of future biosensors. UDP and
UTP interfere with the response of UGAcS. Although UXPS can be used
for cross-checking, a subset of treatment conditions may move the
fluorescence ratios of both sensors toward the same direction, and
it would become difficult to interpret the results. In addition, the
interference makes the quantitative measurement of intracellular UDP-GlcNAc
levels difficult. Directed evolution, machine learning, and computation-assisted
design may be combined to further tune the specificity of UGAcS. Also,
it may be possible to use alternative strategies to develop fluorescent
UDP-GlcNAc sensors with different selectivity profiles. Furthermore,
future research may lead to biosensors with altered affinities, in
additional fluorescence colors, and for other important nucleotide
sugars and carbohydrates.Moreover, nucleotides, such as UTP
and UDP, are important cell
metabolites involved in diverse processes, such as nucleotide biosynthesis,
transcription, purinergic signaling, and apoptotic cell clearance.[45−47] Previous studies have developed several synthetic fluorescent indicators
for UTP and UDP.[48−50] Our genetically encoded UXPS will complement these
efforts and be useful new tools for visualizing UTP and UDP dynamics
in living systems.
Authors: Jun Ito; Thomas Herter; Edward E K Baidoo; Jeemeng Lao; Miguel E Vega-Sánchez; A Michelle Smith-Moritz; Paul D Adams; Jay D Keasling; Björn Usadel; Christopher J Petzold; Joshua L Heazlewood Journal: Anal Biochem Date: 2013-12-01 Impact factor: 3.365
Authors: B Pajak; E Siwiak; M Sołtyka; A Priebe; R Zieliński; I Fokt; M Ziemniak; A Jaśkiewicz; R Borowski; T Domoradzki; W Priebe Journal: Int J Mol Sci Date: 2019-12-29 Impact factor: 5.923
Authors: Paulina Sosicka; Bobby G Ng; Lauren E Pepi; Asif Shajahan; Maurice Wong; David A Scott; Kenjiroo Matsumoto; Zhi-Jie Xia; Carlito B Lebrilla; Robert S Haltiwanger; Parastoo Azadi; Hudson H Freeze Journal: J Cell Biol Date: 2022-09-02 Impact factor: 8.077